CION Ameerpet
If your lymphoma has come back after remission (relapsed) or never fully responded to treatment (refractory), it does not mean options have run out. This guide explains what relapse means and the second-line, transplant and CAR T pathways CION coordinates.
Hearing that your lymphoma has come back — or that it did not respond as hoped — is one of the hardest moments in the whole journey. The first thing to know is that these words describe a change in the treatment pathway, not the end of it. Relapsed lymphoma is lymphoma that went into remission after first-line treatment but has now returned. Refractory lymphoma is lymphoma that did not fully respond to first-line treatment, or that grew again during or very soon after it.
Both situations trigger the same careful first steps: fresh imaging (often a PET-CT), and usually a repeat biopsy of an active site. That is because when lymphoma comes back, the team needs to be sure it is genuinely the same disease — a slow-growing lymphoma can sometimes transform into a more aggressive type, and that changes the plan entirely. Only once relapse is confirmed and re-characterised does the team choose from the "lymphoma came back" options set out below.
This page focuses on the relapse pathway itself. For the full first-line picture — symptoms, subtypes, staging and initial regimens — see our Lymphoma Treatment in Hyderabad page and the main Lymphoma hub.
For aggressive lymphomas, when the disease relapses after first remission, international guidelines still support treatment with curative intent in fit patients — typically second-line (salvage) therapy followed by an autologous stem cell transplant, with CAR T-cell therapy as an option for selected people. Relapse changes the plan, but it does not automatically remove the goal of long-term control. (Source: NCCN Guidelines for B-cell Lymphomas and ESMO clinical practice guidelines.)
At relapse, the pathway splits into several very different directions — and choosing well depends on getting the diagnosis, the timing and the eligibility exactly right. This is where one steering team matters most.
CION performs biopsy and bone-marrow examination directly, so relapse is confirmed on fresh tissue — not assumed from a scan. This catches transformation and rules out mimics before any second-line treatment starts.
Every relapsed or refractory case is discussed by a multidisciplinary tumour board against current NCCN and ESMO guidance, so the second-line choice is deliberate and matched to your subtype and fitness.
Salvage chemotherapy, antibody therapy and targeted therapy are given in-house. Stem cell transplant and CAR T-cell therapy are coordinated through accredited partner facilities.
Even when a transplant or cell infusion happens at a specialist unit, CION manages your referral, supportive care, monitoring and survivorship — so you never fall between teams at the most stressful stage.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just learned your lymphoma has come back or stopped responding? Want to understand your second-line, transplant and CAR T options before deciding? CION's haemato-oncology team is here.
Before any second-line treatment, the team rebuilds an accurate picture of the disease. This is not a formality — the results directly change what comes next.
CION performs the biopsy, bone-marrow exam and molecular workup directly, and every result is brought to the tumour board so the second-line decision rests on complete information.
Once relapse is confirmed, the team chooses from a structured set of options. Which one fits depends on the subtype, how long remission lasted, your previous treatment and your fitness. The main directions are set out below — described by treatment approach, not by specific drug names (for named regimens, see our treatment page).
| Pathway | Who it may suit | Delivered by |
|---|---|---|
| Salvage systemic therapy (alkylating chemotherapy + anti-CD20 antibody) | Fit patients with relapsed aggressive lymphoma, aiming to shrink disease before transplant | CION — in-house |
| Autologous stem cell transplant | Chemo-sensitive relapsed aggressive lymphoma after successful salvage therapy | Coordinated — accredited partner |
| CAR T-cell therapy | Selected patients whose lymphoma relapses after, or is not suited to, transplant | Coordinated — accredited partner |
| Antibody-based therapy & bispecific antibodies | Various subtypes; can be used alone or combined with other approaches | CION — in-house |
| Targeted therapy | Lymphomas with a matching molecular marker | CION — in-house |
| Clinical trial | When a trial offers access to a promising newer approach | Coordinated referral |
This table is a general guide; the right pathway is decided individually at the tumour board. Stem cell transplant and CAR T-cell therapy are delivered at accredited partner facilities, with CION coordinating eligibility, referral and follow-up.
These are the most advanced options in the relapse pathway. Both are delivered at accredited partner facilities, with CION coordinating the whole journey around them.
For chemo-sensitive relapsed aggressive lymphoma, the usual sequence is salvage therapy to achieve another remission, followed by an autologous stem cell transplant — high-dose therapy supported by the reinfusion of your own previously collected stem cells. CION arranges the eligibility assessment, salvage phase and referral. A donor (allogeneic) transplant is considered in more specific situations.
CAR T-cell therapy re-engineers your own immune cells to recognise and attack the lymphoma. For selected patients — for example, when lymphoma relapses after a transplant or a transplant is not suitable — it has become an important option. Because it needs specialised facilities and monitoring, CION coordinates the referral, prepares you, and manages care before and after the infusion.
Salvage chemotherapy (and side-effect management), antibody and targeted therapy, involved-site radiation, biopsy, bone-marrow examination, supportive care and survivorship are all provided in-house. You can also review what to expect during an infusion and about chemo ports and central lines before you start.
Outlook in lymphoma varies widely by subtype and is generally more favourable than many people fear. Across published series, roughly 80–90% of people with Hodgkin lymphoma and around 60–70% of people with diffuse large B-cell lymphoma achieve long-term survival with modern treatment — and effective second-line options exist when the disease relapses. Figures vary by individual, stage and fitness, and no team can promise a cure. (Source: published survival series referenced in NCCN and ESMO lymphoma guidelines.)
A second opinion is especially valuable at relapse, because this is the exact point where the pathway splits into several different directions and the decision benefits from fresh eyes. Consider one if:
CION offers a dedicated, free written second-opinion service reviewed by our haemato-oncology team. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726. You can also meet the lymphoma doctors who would review your case.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if a repeat biopsy or molecular re-testing has not yet been arranged since your lymphoma came back.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.The two words describe two different situations, though people often group them together. Relapsed lymphoma means the lymphoma responded to first treatment and went into remission, but then came back — sometimes months, sometimes years later. Refractory lymphoma means the lymphoma did not respond well to first-line treatment in the first place, or grew again during or very soon after it. Both change what happens next: the team confirms the return with fresh imaging and usually a repeat biopsy, then plans a second-line approach. If your lymphoma has come back or never fully cleared, that does not mean options have run out — it means the pathway shifts to a different set of treatments, which we explain below.
The honest answer is that it depends on the lymphoma subtype, how long remission lasted, your earlier treatment and your overall health — but there is usually a structured menu of options. For many people, second-line treatment aims at achieving another remission, sometimes followed by an autologous stem cell transplant. Others may be suited to CAR T-cell therapy, an antibody-based treatment, targeted therapy or a clinical trial. The right path is chosen at a multidisciplinary tumour board. A second opinion can help you weigh these lymphoma-came-back options clearly.
For a meaningful number of people, yes — a second remission and long-term control remain realistic goals, though outcomes vary by individual and no team can promise a cure. Some aggressive lymphomas that relapse can still be treated with curative intent, often using second-line therapy followed by an autologous transplant, or with CAR T-cell therapy in eligible patients. Slow-growing (indolent) lymphomas may not be curable but are frequently very controllable over many years with repeated lines of treatment. Per NCCN and ESMO guidance, the aim, intensity and choice of treatment are matched to the subtype, prior therapy and your fitness — which is exactly what the tumour board weighs up.
When lymphoma returns or fails to clear, the team usually recommends a fresh biopsy of an active site rather than assuming it is the same disease as before. There are three reasons. First, it confirms the lymphoma has genuinely relapsed and is not a different condition (infection or a second cancer can mimic relapse on a scan). Second, a slow-growing lymphoma can transform into a more aggressive type, which changes treatment completely. Third, molecular markers such as CD20, CD30, cell-of-origin or other features can be re-checked to guide antibody-based or targeted therapy. CION performs biopsy and bone-marrow examination directly and reviews every case before planning.
Second-line (also called salvage) treatment is the plan used when first-line treatment has not achieved lasting control. For aggressive lymphomas that relapse, it commonly means a further course of combination therapy — described by drug class such as alkylating chemotherapy plus an anti-CD20 monoclonal antibody — with the goal of shrinking the disease enough to move on to an autologous stem cell transplant. For some subtypes, CAR T-cell therapy or a bispecific antibody may be considered. Specific drug and regimen names are set individually; for those details see our Lymphoma Treatment in Hyderabad page or ask the team directly.
Both stem cell transplant and CAR T-cell therapy are advanced treatments delivered at accredited partner facilities, not in-house at CION. What CION does directly is the coordination: confirming eligibility, arranging the pre-transplant salvage chemotherapy and immunotherapy, performing biopsy and bone-marrow assessment, managing the referral to the transplant or cell-therapy centre, and continuing your follow-up, supportive care and survivorship afterwards. This means you have one team steering the whole pathway even though the transplant or cell infusion itself happens at a specialist unit. You can read more on our stem cell transplant overview and allogeneic (donor) transplant pages.
A second opinion is especially worthwhile at relapse, because this is the point where the path splits into several very different options and the decision benefits from fresh eyes. A relapse review can confirm the diagnosis on a repeat biopsy, check whether molecular re-testing is complete, and lay out whether second-line therapy, an autologous transplant, CAR T-cell therapy or a clinical trial fits your situation. CION offers a free written second opinion reviewed by our haemato-oncology team. You can also explore the lymphoma doctors and facilities available before you decide.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.